<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003116</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU1995T</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-CWRU-1995</secondary_id>
    <secondary_id>NCI-G97-1354</secondary_id>
    <secondary_id>CASE1995T</secondary_id>
    <nct_id>NCT00003116</nct_id>
  </id_info>
  <brief_title>High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer</brief_title>
  <official_title>Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving busulfan, cyclophosphamide, and&#xD;
      filgrastim together with peripheral stem cell transplantation from a sibling donor works in&#xD;
      treating patients with hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and feasibility of using allogeneic peripheral blood progenitor&#xD;
           cell infusions obtained from normal histocompatible sibling donors for reconstituting&#xD;
           bone marrow and immunologic function when given after high-dose&#xD;
           busulfan/cyclophosphamide in patients with a hematologic malignancy.&#xD;
&#xD;
        -  Determine the efficacy of this treatment in these patients.&#xD;
&#xD;
        -  Determine the ability to mobilize hematopoietic progenitor cells from normal donors&#xD;
           given filgrastim (G-CSF) by determining the hematopoietic progenitor cell content of&#xD;
           allogeneic peripheral blood progenitor cell collections.&#xD;
&#xD;
        -  Determine the incidence of engraftment failures in these patients.&#xD;
&#xD;
        -  Determine the incidence of severe acute graft-versus-host disease in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive high-dose oral busulfan every 6 hours on days -8 to -5,&#xD;
      cyclophosphamide IV twice a day on days -4 and -3, and cyclosporine IV over 6 hours on day -1&#xD;
      and then 10 hours on day 0 for 2 doses (allogeneic only). Allogeneic peripheral blood&#xD;
      progenitor cells IV are administered on day 0.&#xD;
&#xD;
      Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after&#xD;
      completion of cell infusion and continuing until blood counts recover.&#xD;
&#xD;
      Patients are followed every month for 2 months, every 3 months for 6 months, and then every 6&#xD;
      months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued over a 15 month period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematopoietic reconstitution measured daily during transplant</measure>
    <time_frame>at months 2, 4, 7, and 10, and then every 6 months until disease progression</time_frame>
  </primary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>high-dose oral busulfan every 6 hours on days -8 to -5</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide IV twice a day on days -4 and -3</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Allogeneic peripheral blood progenitor cells IV are administered on day 0.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically diagnosed:&#xD;
&#xD;
               -  Acute myeloid leukemia in first, second, or third complete remission or first or&#xD;
                  second early relapse&#xD;
&#xD;
               -  Acute lymphoblastic leukemia in first, second, or third complete remission or&#xD;
                  first or second early relapse&#xD;
&#xD;
               -  Hodgkin's lymphoma in second or third remission or first, second, or third&#xD;
                  relapse, or refractory&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma in second or third remission or first, second, or third&#xD;
                  relapse, or refractory&#xD;
&#xD;
               -  Multiple myeloma and plasma cell leukemia in second or third remission or first,&#xD;
                  second, or third relapse, or refractory&#xD;
&#xD;
               -  Myelodysplastic syndrome deemed suitable for allogeneic bone marrow&#xD;
                  transplantation&#xD;
&#xD;
          -  No symptoms or signs of CNS involvement and CNS is disease free on lumbar puncture and&#xD;
             brain CT scan&#xD;
&#xD;
          -  No active meningeal cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  4 to 55 (4 to 60 if donor is identical twin)&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT/SGPT less than 3 times normal&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.1 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min (no greater than 1.5 times normal for children&#xD;
             under 40 kg)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No active angina pectoris requiring nitrates&#xD;
&#xD;
          -  At least 6 months since prior myocardial infarction&#xD;
&#xD;
          -  No major ventricular arrhythmia&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45% on MUGA&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe or symptomatic restrictive or obstructive lung disease&#xD;
&#xD;
          -  FEV_1 greater than 50% of predicted&#xD;
&#xD;
          -  DLCO greater than 50% of predicted&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No severe central or peripheral neurologic abnormality&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Must have HLA-A,B,C,D/DR identical sibling age 4 to 65, in good health&#xD;
&#xD;
          -  No insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  No major thyroid or major adrenal dysfunction&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  HTLV-I and HTLV-II negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No excessive anthracycline exposure, unless endomyocardial biopsy shows less than&#xD;
             grade 2 drug effect and cardiac scan shows at least 50% ejection fraction&#xD;
&#xD;
          -  At least 1 year since prior autologous bone marrow or peripheral blood progenitor cell&#xD;
             transplant or allogeneic bone marrow transplant&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior excessive carmustine and bleomycin&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent nitroglycerin for angina pectoris&#xD;
&#xD;
          -  No concurrent anti-arrhythmic drugs for major ventricular dysrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillard M. Lazarus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hosptials Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hillard Lazarus, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

